Japanese drugmaker Kyowa Hakko Kirin (TY: 4151) revealed that it launched the type 2 diabetes drug Onglyza (saxagliptin hydrate), originated by US pharma major Bristol-Myers Squibb (NYSE: BMY) in Japan on July 9.
Onglyza provides a new option in the treatment of type 2 diabetes and is therefore expected to help healthcare professionals and patients to manage type 2 diabetes. The price is 110.2 yen ($1.09) for a 2.5mg tablet and 166 yen for a 5mg tablet.
Otsuka’s “ground-breaking” delamanid progam
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze